cytarabine and Multiple Sclerosis, Relapsing-Remitting

cytarabine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alcalá, C; Boscá, I; Carcelén-Gadea, M; Casanova, B; Cervelló, A; Coret, F; de la Rubia, J; Gascón, F; Gil-Perotin, S; Hernández-Boluda, JC; Jarque, I; Mallada, J; Navarré, A; Pérez-Miralles, F; Sanz, J; Sanz, MA; Solano, C	1
Barnett, MH; Barnett, Y; Ford, CD; Hendrawan, K; Khoo, ML; Kyle, KA; Ma, DDF; Ma, KC; Massey, JC; Milliken, ST; Moore, JJ; Sutton, IJ; Zaunders, JJ; Zivadinov, R	1
Atlas, SW; Bollen, AW; Green, AJ; Langer-Gould, A; Pelletier, D	1

Trials

1 trial(s) available for cytarabine and Multiple Sclerosis, Relapsing-Remitting

Article	Year
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:5 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult	2019

Article

Year

Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:5

Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult

2019

Other Studies

2 other study(ies) available for cytarabine and Multiple Sclerosis, Relapsing-Remitting

Article	Year
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:7 Topics: Adult; Animals; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Rabbits; Transplantation, Autologous; Treatment Outcome	2017
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. The New England journal of medicine, 2005, Jul-28, Volume: 353, Issue:4 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Aphasia; Ataxia; Brain; Cytarabine; Humans; Integrin alpha4; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Opportunistic Infections; Paresis	2005

Article

Year

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:7

Topics: Adult; Animals; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Rabbits; Transplantation, Autologous; Treatment Outcome

2017

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

The New England journal of medicine, 2005, Jul-28, Volume: 353, Issue:4

Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Aphasia; Ataxia; Brain; Cytarabine; Humans; Integrin alpha4; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Opportunistic Infections; Paresis

2005